Over the last decade, technological advances have revolutionised efforts to understand the
role played by microbes in airways disease. With the application of ever more sophisticated …

Importance Macrolide antibiotics such as erythromycin may improve clinical outcomes in
non–cystic fibrosis (CF) bronchiectasis, although associated risks of macrolide resistance …

Background The delivery of antipseudomonal antibiotics by inhalation to Pseudomonas
aeruginosa-infected subjects with non-cystic fibrosis (CF) bronchiectasis is a logical …

Rationale Despite the potentially important roles for infection in adult non-cystic fibrosis (CF)
bronchiectasis disease progression, the bacterial species present in the lower airways of …

Rationale: Although airway microbiota composition correlates with clinical measures in non–
cystic fibrosis bronchiectasis, these data are unlikely to provide useful prognostic information …

Background Long-term macrolide treatment has proven benefit in inflammatory airways
diseases, but whether it leads to changes in the composition of respiratory microbiota is …

Macrolide antibiotics have established efficacy in the management of cystic fibrosis and
diffuse panbronchiolitis—uncommon lung diseases with substantial morbidity and the …

Rationale: Despite growing evidence for the roles of airway remodeling and bacterial
infection in the progression of non–cystic fibrosis bronchiectasis, relationships between …

Background Prior microrheologic assessments of selected, microlitre plugs of cystic fibrosis
(CF) sputum suggest no intrinsic rheologic abnormality. However, such analyses may not be …

Chronic bacterial lung infections associated with non-cystic fibrosis bronchiectasis represent
a substantial and growing health-care burden. Where Pseudomonas aeruginosa is the …